Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.31 |
| ▸ | PGR | P06401 | 3/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7883408 | 0.83 | TRPM5 (0.33) | TRPM5EPAS1PGR | |
| SCHEMBL29672154 | 0.78 | TRPM5 (0.39) | TRPM5PGRGRM2 | |
| SCHEMBL504920 | 0.76 | FADS1 (0.39) | TRPM5RIPK1EPAS1PGRGRM2 | |
| SCHEMBL505411 | 0.69 | PGR (0.34) | TRPM5RIPK1PGRGRM2 | |
| SCHEMBL8860347 | 0.68 | GRM2 (0.38) | TRPM5EPAS1PGRGRM2 | |
| SCHEMBL504747 | 0.68 | TRPM5 (0.34) | TRPM5RIPK1EPAS1PGR | |
| SCHEMBL16412281 | 0.65 | TRPM5 (0.38) | TRPM5RIPK1PGR | |
| SCHEMBL15272344 | 0.65 | TRPM5 (0.38) | TRPM5RIPK1PGR | |
| SCHEMBL9818082 | 0.64 | ESR2 (0.55) | — | |
| SCHEMBL454692 | 0.64 | CHRNB2 (0.38) | TRPM5PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | TRPM5 286/4885RIPK1 1295/4885EPAS1 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.